Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus TOLTERODINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus TOLTERODINE TARTRATE.
CANTIL vs TOLTERODINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5) with relative selectivity for the bladder over salivary glands. Reduces detrusor muscle contractility and bladder pressure.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
2 mg orally twice daily. May be reduced to 1 mg orally twice daily based on tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life is 2-3 hours in extensive metabolizers (CYP2D6) and approximately 9 hours in poor metabolizers. In clinical context, dosing interval is adjusted in poor metabolizers (e.g., 2 mg twice daily reduced to 2 mg once daily).
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal (77%) and fecal (17%): approximately 14% as unchanged tolterodine, 51% as the active 5-hydroxymethyl metabolite, and 12% as other metabolites. Biliary excretion contributes minimally.
Category C
Category A/B
Anticholinergic / Antispasmodic
Anticholinergic